CollPlant Biotechnologies (NASDAQ:CLGN) Earns Buy Rating from D. Boral Capital

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $14.00 target price on the stock. D. Boral Capital’s target price points to a potential upside of 229.53% from the stock’s previous close.

Several other research firms have also issued reports on CLGN. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of CollPlant Biotechnologies in a research note on Wednesday, August 21st. EF Hutton Acquisition Co. I raised shares of CollPlant Biotechnologies to a “strong-buy” rating in a research report on Monday, August 5th.

CollPlant Biotechnologies Stock Down 0.4 %

Shares of NASDAQ:CLGN opened at $4.25 on Wednesday. The stock has a market cap of $48.67 million, a price-to-earnings ratio of -2.76 and a beta of 0.44. The business’s 50 day moving average is $4.30 and its 200 day moving average is $4.85. CollPlant Biotechnologies has a 12-month low of $3.31 and a 12-month high of $6.99.

Institutional Investors Weigh In On CollPlant Biotechnologies

Hedge funds have recently made changes to their positions in the business. Pinnacle Associates Ltd. increased its holdings in CollPlant Biotechnologies by 6.4% during the second quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock worth $2,805,000 after buying an additional 33,905 shares during the last quarter. Villere ST Denis J & Co. LLC increased its stake in shares of CollPlant Biotechnologies by 24.4% during the 3rd quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock worth $2,407,000 after purchasing an additional 95,000 shares during the last quarter. Finally, Benjamin Edwards Inc. purchased a new stake in shares of CollPlant Biotechnologies during the 3rd quarter worth approximately $112,000. 21.69% of the stock is currently owned by institutional investors.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.